PATENT CLAIM ANALYSIS

Application Number: 15879294
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-06
Patent Classification: ["424", "134100"]

Abstract:
Ophthalmic formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided suitable for intravitreal administration to the eye. The ophthalmic formulations include a stable liquid formulation and a lyophilizable formulation. Preferably, the protein antagonist has an amino acid sequence of SEQ ID NO:4.

Claim (Index 16):
The formulation of  claim 12 , wherein the organic co-solvent is polysorbate 20.

Metadata:
- Claim Count in Document: 23.0
- Percentile: 86.0
- Lexical Diversity: 1.23256
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15151776', '15095606', '13914996', '11818463', '12560885']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8052700039906004
- 35 USC 102 Novelty (BERT): 0.5920492167621115
- Combined Prediction Score: 0.7839479252677516
- Mean Citation Score: 511.176478
- Max Citation Score: 527.5613
- Similarity Product: 419.7169830496906

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test